Background {#Sec1}
==========

The spondyloarthritis (SpA) group includes a number of similar inflammatory diseases, with varying degrees of inflammation in peripheral joints, entheses, spine, gut, skin, eyes and other organs. In a clinical setting SpA-disease is often categorized through its most prominent feature, e.g. psoriatic arthritis (PsA), SpA associated with inflammatory bowel disease (IBD), reactive arthritis (ReA) or axial SpA. In axial SpA the most prominent feature is chronic back pain, usually accompanied with symptoms of inflammatory back pain (IBP) and often with signs of inflammation in the sacroiliac joints and spine \[[@CR1], [@CR2]\]. Axial SpA having resulted in radiographically detectible sacroilitis is clinically diagnosed as ankylosing spondylitis (AS) \[[@CR3]\], while axial SpA without radiographic sacroilitis may be classified as non-radiographic axial-SpA, according to the "Assessment of SpondyloArthritis" (ASAS) criteria for axial SpA\[[@CR1]\].AS is known to be more common in men and non-radiographic axial SpA in women, and the progression rate from non-radiographic axial SpA to AS is considered to be around 10--12 % over 2 years \[[@CR1]\].

The most common presentation of axial SpA is IBP \[[@CR2]\], wherefore this is one of the key symptoms that are asked for in a clinical setting, when trying to identify patients with axial SpA. However, neither the modified New York criteria for AS \[[@CR4]\] nor the current ASAS criteria for axial SpA\[[@CR5]\] includes past or present IBP as a compulsory feature. In fact, both the sensitivity and the specificity of IBP for axial SpA, classified according to the ASAS-criteria in the setting of established axial SpA or chronic back pain, is 70--80 % \[[@CR6], [@CR7]\], illustrating the fact that not all patients with axial SpA have IBP and that axial disease activity may vary over time \[[@CR8]\].

The frequency and disease activity of axial disease in other subtypes of SpA, where chronic back pain is not the predominant symptom, i.e. patients not referred to a rheumatologist due to back pain or patients with a predominantly peripheral disease, is less studied. In one study, comparisons between patients with AS, PsA and SpA associated with IBD (all with radiographic sacroilitis) indicated no significant differences with regard to axial disease activity\[[@CR9]\]. This comparison was however limited by excluding all forms of non-radiographic axial disease and by only focusing on patients with typical radiographic findings of sacroilitis. In patients with PsA attending a rheumatology clinic the frequency of IBP has been described to be as high as 49 % \[[@CR10]\], and one recent study demonstrated a high frequency of IBP among young patients with cutaneous psoriasis (17 %) \[[@CR11]\], which may indicate that axial disease is more common in psoriasis than previously thought. In conclusion, there is relatively little knowledge of how common symptoms of IBP are among different subtypes of SpA and how this is reflected in patient-perceived disease activity.

Our objectives in this cross-sectional, population based, study was to firstly, assess the proportion of patients with IBP within different subtypes of SpA, and secondly, to compare self-reported disease activity between the groups with IBP, in order to explore possible differences with regard to self-perceived severity. The study is based on a well-established and validated cohort of clinically diagnosed SpA patients, the SpAScania cohort.

Methods {#Sec2}
=======

Setting {#Sec3}
-------

This cross-sectional study was performed in the county of Skåne in southern Sweden, with a population of 1.2 million. Population-based healthcare registers were used to identify cases with SpA in Skåne, to whom a postal survey was sent in 2009.

Data sources {#Sec4}
------------

The registers used in this study were the Skåne Health Care Register (SHCR) \[[@CR12]\] and the Prescribed Drugs Register. All data in the registers were linked to the patients' personal identification numbers (PIN), which are unique identifiers given to all residents in Sweden. The PIN allows the information on individuals in different registers to be cross-linked \[[@CR13]\]. Additional file [1](#MOESM1){ref-type="media"}: Table S1 presents the ICD-10 (International Classification of Diseases) and ATC-codes (Anatomical Therapeutic Chemical codes) \[[@CR14]\] that were used in the study.

The SHCR contains information from every patient visit to healthcare providers included in the national reimbursement system (the majority). Outpatient, inpatient, primary, and specialized care providers are all included. The data collected include disease codes, according to the Swedish version of the ICD-10 \[[@CR15]\] (up to eight codes/visit), dates of visit/admission/discharge, and other administrative data.

The Prescribed Drugs Register collects information on all drugs dispensed in Sweden since July 2005: date of prescription/dispensation and the prescribed dose. The drugs are classified according to the ATC classification system \[[@CR14]\].

Ethical approval {#Sec5}
----------------

The Regional Ethical Review Board at Lund University, Sweden, approved the study (301/2007, 406/2008). Informed consent was obtained in compliance with the Declaration of Helsinki.

Study population {#Sec6}
----------------

All patients in the SHCR who were ≥15 years of age and had a healthcare visit to a physician between January 2003 and December 2007 that resulted in an ICD-10 code that indicated a SpA diagnosis were identified (*N* = 6799, the SpAScania cohort). The diagnoses used were those for AS (ICD-10 codes M45 and M08.1), undifferentiated SpA/Sacroilitis (ICD-10 codes M46.0, M46.1, M46.8 and M46.9), IBD-associated arthritis (ICD-10 codes M07.4 and M07.5), PsA (ICD-10 codes L40.5 and M07.0-3), and ReA (ICD-10 codes M02.0-2, M02.8--9, M01.2 and M03.2). The validity of the SpA-diagnoses in the SpAScania cohort have previously been evaluated and found to be high \[[@CR12], [@CR16]\].

In 2009, all of the subjects identified in the procedure above, ≥18 years old, and still living in the county, were invited to participate in a postal survey (*N* = 5771). For the same subjects, the ICD-10 codes for the common SpA-related disease manifestations (IBD, psoriasis, and anterior uveitis), registered at a visit to a physician in primary or secondary care between 1998 and 2009 were extracted from the SHCR (see Additional file [1](#MOESM1){ref-type="media"}: Table S1). The same subjects were also linked to the Prescribed Drugs Register and the ATC-codes for the following SpA-related drugs (available for 2005--2009) were collected: the synthetic disease-modifying anti-rheumatic drugs (sDMARDs): methotrexate and sulphasalazine; and the tumor necrosis factor alpha inhibitors (TNFi): etanercept and adalimumab. Infliximab was not included as this is normally not collected at a pharmacy. The survey included a number of well-validated generic and disease-specific patient-reported outcome measures (PROMs): spinal pain, the patient's global assessment of back disease and fatigue, the Bath Ankylosing Spondylitis Activity Index (BASDAI), the Bath Ankylosing Spondylitis Functional Index (BASFI) (all measured 0--10, best to worst, on a numerical rating scale (NRS)) and the European Quality of Life-5 Dimensions index (EQ-5D; higher score = better health)\[[@CR17]\]. Included were also questions about frequency and duration of back pain; the different features of inflammatory back pain (IBP); family history of SpA; current pharmacological treatment and history of psoriasis and IBD.

Case definitions {#Sec7}
----------------

AS was defined as having received an ICD-10 code for AS at ≥1 physician visit during the 2003--2007 study period. AS is per definition an axial disease and the ICD-codes for AS in the SHCR have been validated previously \[[@CR12]\]. All the remaining patients in the cohort had received another clinical diagnosis of SpA, and never a diagnosis of AS, during the 2003--2007 study period. This cohort was further divided into psoriatic arthritis (PsA) (defined as having ever either received a diagnosis for psoriasis in addition to a diagnosis of SpA, and/or psoriatic arthritis) and "other-SpA" (having never received neither a diagnosis of AS nor PsA). Among the responders to the survey we identified all cases, within the AS, PsA and "other-SpA" groups, with current IBP, based on self-reported back pain (pain in the back or buttocks) for ≥3 months within the last 12 months and fulfilling the Berlin criteria for IBP. The Berlin criteria for IBP (rather than the ASAS criteria) were used for identification of IBP since they may have a higher specificity and may also perform better in PsA \[[@CR6], [@CR7], [@CR11]\].

Reliability analysis {#Sec8}
--------------------

To compare the concordance (and thus indirectly the reliability) of data collected by the survey and the registers (SHCR and the Prescribed Drugs Register), kappa-values for variables that could be identified in both sources were calculated. The variables included were current treatment with methotrexate, sulphasalazine, etanercept, or adalimumab, and existence of psoriasis or IBD.

Statistical methods {#Sec9}
-------------------

The frequency and proportion of cases with current IBP was determined for each of the three groups, AS, PsA and other-SpA, as a total and stratified by sex and 15-year interval age groups. Between group comparisons were performed using Fisher's exact test.

The three groups of AS, PsA and other-SpA, with current IBP, were compared in terms of levels of PROMs and frequencies of SpA-related disease manifestations, and pharmacological treatment by using independent-sample t-tests and Fisher's exact test. Due to the multiple testing performed on the same data set, a Bonferroni correction was performed to counteract the risk of a type I error. More specifically comparisons of frequency of PROMs and pharmacological treatment were done using a *p*-value with the cut-off of 0.00125, obtained through a Bonferroni correction based on a statistical significance of 0.05 and the number of comparisons being 40.

SAS version 9.3 for Windows was used for the aggregation of data and SPSS version 21 for Windows was used for statistical analyses.

Results {#Sec10}
=======

The SpAScania cohort {#Sec11}
--------------------

In total, 5771 individuals received ICD-10 codes for AS, PsA and other SpA in 2003--2007, were ≥18 years old, and were living in the county at the time of the survey (2009). Their mean age was 54.7 years and 53 % were women. Of these, 1423 (41 % women) had an AS diagnosis and 2280 (57 % women) had PsA (had ever received a diagnosis of PsA or alternatively any other non-AS SpA diagnosis in combination with a diagnosis of psoriasis) and 2028 (57 % women) had another SpA diagnosis. Registered data for six responders and 32 non-responders were incomplete and data for two additional subjects were missing when assembling the data-sets, these were excluded from further analyses. Complete responses to the questionnaire were received from 48 % (*n* = 2785) of recipients. A flow chart showing the analysis steps is presented in Fig. [1](#Fig1){ref-type="fig"}.Fig. 1Flow chart depicting the selection of the SpAScania cohort. Legend: The figure shows the identification of patients with ankylosing spondylitis (AS), psoriatic arthritis (PsA) and other spondyloarthritis (SpA) in the Skåne Health Care Register, the proportions reporting current inflammatory back pain (back pain ≥ 3 months within the last 12 months and fulfilling the Berlin criteria for IBP), the response to the questionnaire, and the subsequent analyses

Of the 2785 responders 319 (43 % of the AS group, 43 % women) had AS with symptoms of current IBP (reported back pain ≥3 months within the last 12 months and fulfilled the Berlin criteria for IBP), 409 (31 % of the PsA group, 68 % women) had PsA with current IBP and 282 (39 % of the other-SpA group, 69 % women) had other-SpA with current IBP (Table [1](#Tab1){ref-type="table"}) The differences in the proportions with current IBP was statistically significant for AS and other-SpA compared to PsA but not for AS compared to other-SpA. The occurrence of IBP was highest in the age-group 45--59, where the difference between AS and PsA was also most pronounced, and decreased after the age of 60. The proportions with IBP were, furthermore, overall higher in women compared to men, although it reached statistical significance only in other-SpA and PsA, but not in AS. (Table [1](#Tab1){ref-type="table"}).Table 1Frequency and proportion with current inflammatory back pain among AS, PsA and other-SpA. Legend: For each group only data for responders to the postal survey (*N* = 2785) are included, stratified first on sex and then on age-groups. Registered data for 6 responders were incomplete and are thus excluded from the studyAnkylosing Spondylitis (AS) *N* = 744Psoriatic arthritis (PsA) *N* = 1310*p*-value AS vs PsAOther Spondyloarthritis (SpA) *N* = 725*p*-value AS vs SpA*p*-value PsA vs SpAMen (%)451 (61)552 (42)\<0.001286 (39)\<0.0010.240Current IBP^a^ (%)319 (43)409 (31)^b^\<0.001282 (39)^c^0.1120.001SexWomen *N* = 293Men *N* = 451Women *N* = 758Men *N* = 552Women *N* = 439Men *N* = 286Current IBP *N*(%)137 (47)182 (40)280 (37)129 (23)195 (44)87 (30)*p*-value men vs women0.111\<0.001\<0.001Age groupsTotalCurrent IBP (%)TotalCurrent IBP (%)TotalCurrent IBP (%)15--294212 (29)509 (18)0.3197229 (40)0.2310.01030--4419082 (43)24173 (30)0.00618574 (40)0.6000.04045--59243126 (52)463172 (37)\<0.00122296 (43)0.0770.13360--7422686 (38)464133 (29)0.01519864 (32)0.2240.354\>754313 (30)9222 (24)0.3034819 (40)0.5190.077All *p*-values are based on Fisher's exact test^a^IBP = inflammatory back pain, according to the Berlin criteria^b^Proportion of IBP in psoriatic arthritis compared to ankylosing spondylitis *p* \< 0.001^c^Proportion of IBP in other-spondyloarthritis compared to ankylosing spondylitis *p* = 0.112

PROMs and pharmacological treatment {#Sec12}
-----------------------------------

All PROMs (spinal pain, fatigue, patients global, BASFI and EQ-5D) were similar in the three groups, apart from BASDAI which was significantly higher in the PsA group compared to the AS-group. Using a significance level of 0.05 (without Bonferroni correction) resulted in additional significantly worse scores for PsA compared to AS for fatigue, and for other-SpA compared to AS for spinal pain and BASDAI. The mean differences between AS, PsA and other-SpA in PROMs were however in absolute numbers small and within a range that is normally not considered clinically significant \[[@CR18], [@CR19]\]. Table [2](#Tab2){ref-type="table"} summarizes the demographics, SpA features, PROMs, and pharmacological treatment of the three groups with current IBP.Table 2Spondyloarthritis features, pharmacological treatment, and PROMs in AS, PsA or other-SpA, with IBPAS with current IBP^a^ *N* = 319PsA with current IBP^a^ *N* = 409*p*-value\*Other-SpA with current IBP^a^ *N* = 282*p*-value\*\**p*-value\*\*\*DemographicAge 2009, mean (sd)^b^54 (13)57 (13)53 (15)Sex, N men (%)^b^182 (57)129 (32)\<0.00187 (31)\<0.0010.860SpA-related disease, *N* (%)Uveitis^b^63 (20)9 (2)\<0.00137 (13)\<0.001\<0.001Psoriasis^b^19 (6)407 (100)\<0.0010Inflammatory bowel disease^b^25 (8)21 (5)0.90136 (13)0.7060.001PROMS, mean (95 % Cl)NRS-spinal pain^c^5.9 (5.6−6.1)6.1 (5.9−6.4)0.0686.2 (6.0−6.5)0.0370.688NRS-fatigue^c^5.8 (5.6−6.1)6.2 (5.9−6.4)0.0446.1 (5.8−6.4)0.1170.547NRS-patients global^c,d^5.2 (4.9−5.4)5.4 (5.2−5.6)0.1885.5 (5.2−5.7)0.0870.850BASDAI^c^5.1 (4.8−5.3)5.7 (5.5−5.8)\<0.0015.5 (5.3−5.8)0.0060.530BASFI^c^4.4 (4.2−4.7)4.8 (4.5−5.0)0.0934.4 (4.1−4.7)0.9730.093EQ-5D^c^0.68 (0.66−0.70)0.65 (0.63−0.67)0.0620.67 (0.64−0.69)0.3620.421Treatment, *n* (%)Etanercept^b^27 (9)54 (13)0.04415 (5)0.1500.001Adalimumab^b^12 (4)32 (8)0.0279 (3)0.8250.013Methotrexate^b^37 (12)151 (37)\<0.00133 (12)1.000\<0.001Sulphasalazine^b^28 (9)14 (3)0.00324 (9)1.0000.006*Abbreviations*: *AS* ankylosing spondylitis, *IBD* inflammatory bowel disease, *NRS* numerical rating scale 1--10, *BASDAI* bath ankylosing spondylitis activity index, *BASFI* bath ankylosing spondylitis functional index, *PROMs* patient-reported outcome measures, *IBP* inflammatory back painBased on 2785 spondyloarthritis patients in the Skåne Health Care Register who responded to a questionnaire, registered data for 6 responders were incomplete and was thus excluded\*^,^\*\*AS with current IBP vs. PsA and other-SpA with current IBP, respectively\*\*\*PsA with current IBP vs. other-SpA with current IBP^a^Current IBP: ≥3 months of back pain in the preceding year and fulfilling the Berlin criteria for inflammatory back pain (IBP)^b^Data from the register (SpA-related disease 1998--2009; treatment 2005--2009)^c^Data from the survey^d^Patient's global assessment of back disease

PsA, with current IBP, used methotrexate more frequently than the AS and other-SpA groups with current IBP and etanercept more frequently than the other-SpA group. No differences in treatment were observed between AS and other-SpA with current IBP.

Stratifying the groups by sex revealed overall worse results for all PROMs in women compared to men, but similar results with regard to differences in men and women between AS, PsA and other-SpA as those seen in the overall comparison (Additional file [1](#MOESM1){ref-type="media"}: Table S2).

Responders vs. non-responders and reliability analysis {#Sec13}
------------------------------------------------------

Table [3](#Tab3){ref-type="table"} shows the differences between the responders and non-responders in terms of age, gender, SpA diagnosis, and pharmacological treatment. The non-responders differed significantly from the responders in that they were younger, and more likely to have been given a diagnosis of ReA. Non-responders also were slightly less likely to have been given diagnoses of AS, undifferentiated SpA, and PsA. These differences in diagnoses probably explain why the non-responders also had lower frequencies of use of sDMARDs and TNF-inhibitors.Table 3Comparison of responders and non-responders, for age, sex, spondyloarthritis diagnosis and pharmacological treatment. Legend: Both responders and non-responders may have received more than one diagnosis or pharmacological treatment during the respective time frameResponders (*n* = 2785)^a^Non-responders (*n* = 2986)^a^*p*-valueDemographicsAge, median (Q1, Q3)57 (45, 66)53 (41, 66)\<0.001Sex, n women (%)1494 (49)1551 (51)0.290Diagnoses, *n* (%)Ankylosing spondylitis744 (27)679 (23)0.001Psoriatic arthritis1285 (46)944 (32)\<0.001Undifferentiated SpA411 (15)300 (10)\<0.001Sacroiliitis157 (6)209 (7)0.035Reactive arthritis359 (13)924 (31)\<0.001IBD-associated arthritis66 (2)65 (2)0.659Spine enthesiopathy13 (1)12 (0)0.842Psoriatic spondylitis20 (1)19 (1)0.750Treatment, *n* (%)Methotrexate936 (34)538 (18)\<0.001Sulphasalazine297 (11)159 (5)\<0.001Etanercept323 (12)153 (5)\<0.001Adalimumab168 (6)94 (3)\<0.001Based on 5771 spondyloarthritis patients in the Skåne Health Care Register who were invited to participate in a survey. All data in the table is based on the health care registers*Abbreviations*: *SpA* spondyloarthritis, *IBD* inflammatory bowel disease^a^40 subjects had incomplete data and are excluded. Comparisons were performed using independent-sample t-tests and Fisher's exact test

To indirectly examine the reliability of the survey and registry-derived data, kappa-values for variables that were captured by both data sources were calculated. The kappa-values (proportion of agreement in parenthesis) for SpA disease manifestations and current treatment were IBD, k = 0.65 (95 %); psoriasis, k = 0.70 (85 %); methotrexate, k = 0.87 (94 %); sulphasalazine, k = 0.91 (97 %); etanercept, k = 0.95 (98 %); and adalimumab, k = 0.95 (99 %).

Discussion {#Sec14}
==========

In this population-based study the frequencies of current IBP were high in all three groups with AS, PsA and other-SpA. The proportion of patients afflicted with IBP was higher for women, compared to men, in PsA and other-SpA, but equal in AS, and the proportion of cases reporting current IBP was highest in AS, yet only 43 %. The three groups with current IBP had similar levels of self-perceived health status, reflecting pain, disease activity, function, and quality of life, which support the validity of IBP in non-AS SpA groups. However, there was a consistent trend for worse reports in the PsA and other-SpA groups compared to AS.

In analogy to our study, others have reported that AS and non-radiographic axial SpA patients attending rheumatology units have opposite gender distributions \[[@CR2], [@CR20], [@CR21]\]. However, it should be stressed that we are comparing patients with different subtypes of clinically diagnosed SpA reporting current IBP, and not axial SpA according to the ASAS classification criteria, making comparisons to other studies difficult. The observation that AS and other axial SpA have similar health status is supported by a study of consecutive axial SpA patients at five rheumatology clinics in Germany, where compared with AS, the non-radiographic axial SpA phenotype was associated with equivalent self-reported health status \[[@CR22]\]. One possible explanation for the relatively poor health status in PsA and other-SpA could be the female predominance in our groups with IBP in combination with PsA and other-SpA, since it is known that women in general report worse health status than men \[[@CR23]--[@CR26]\]. However, this notion is not supported by our analyses stratified by sex, were the trends observed for the PROMs in the gender-mixed groups were similar for both men and women separately (Additional file [1](#MOESM1){ref-type="media"}: Table S2). Another possible explanation for the poorer health status of these two groups could be insufficient treatment. However, our study showed that there were no statistically significant differences in pharmacological treatment between the AS and the "other-SpA" group and that the PsA-group was treated more frequently than the AS group, although non-pharmacological treatment was not accounted for. Since both psoriasis, with and without arthritis, as well as IBD are indications for treatment with sDMARDs and TNFi in Sweden \[[@CR27], [@CR28]\], the relatively high frequency of pharmacological treatment in these groups could be related to concurrence of psoriasis, IBD or peripheral arthritis. On the other hand, the similarly elevated mean levels of spinal pain, in the AS and non-AS SpA subgroups with current IBP may support the validity of IBP and presence of axial disease in these groups. In line with our results, a recent study based on the NHANES cohort found that there was a high frequency (17 %) of IBP in a group with "self-reported medically diagnosed psoriasis" \[[@CR11]\]. The fact that only 43 % of patients with AS hade current IBP may be explained by the fluctuating course of symptoms, treatment effects and possibly due to decreasing symptoms with higher age.

Some limitations of the study must be discussed. First, the study setting relied on data from a postal survey and health care registers, which meant that we could not retrieve the physicians' expert opinions regarding the existence of axial disease (i.e.*,* the "golden standard"). Second, the setting and study design also precluded assessment of biomarkers or imaging, which are central to both the modified New York criteria for AS and the ASAS criteria for axial SpA. However, validation studies based on a review of the clinical records in our setting have demonstrated a high validity for the diagnosis of AS on the basis of ICD-10 codes \[[@CR12], [@CR29]\]: over 80 % fulfilled the modified New York criteria, while 89 % fulfilled one or more of the criteria that are commonly used to classify patients with SpA. In this validation process, we also found that over 90 % of cases identified as undifferentiated SpA fulfilled at least one of the commonly used classification criteria of SpA, while only a minority fulfilled the modified New York criteria for AS \[[@CR29]\]. Furthermore, a validation study of the ICD-10 codes for psoriasis in the cohort of the present study yielded positive predictive values \[PPV\] of at least 81 % \[[@CR16]\]. In our study, the frequencies observed for anterior uveitis, psoriasis, and IBD in the AS group were also similar to those reported in other studies of radiographic axial SpA \[[@CR20]\], also supporting the validity of the diagnoses. Based on these validation exercises, and the frequencies of SpA-related disease manifestations, we believe that the clinical diagnoses of SpA analyzed in this study are valid. Third, the high rate of non-responders may have affected the results, especially for the group with other-SpA. The lower frequencies of treatment with sDMARD and TNFi among non-responders could indicate lower rates of symptoms in this group, which has to be taken into consideration when trying to generalize our results.

The present study also has several strengths. It is one of the first population-based studies to assess and compare the frequency of current IBP within different SpA subtypes and to compare health status. Second, the information was gathered from several different sources. In particular, information regarding pharmacological treatment was gathered from a completely independent data source. Moreover, analysis of the reliability of our findings by comparing the data from the survey and the registers yielded kappa statistics that indicated a "good" reliability for IBD and psoriasis (k = 0.65 and 0.70, respectively) and a "very good" reliability for the pharmacological treatments (k = 0.87--0.95)\[[@CR30]\].

Conclusions {#Sec15}
===========

To sum up, our results suggest that the frequency of patients with current IBP is high in AS, PsA and other SpA, although the proportion is highest for AS. The impact on health status is, however, similar for patients with AS, PsA and other SpA with current IBP supporting the validity of this symptom in non-AS SpA groups. Our data also indicate that in our setting, this may already largely being recognized by the healthcare services; given that the groups with PsA and other-SpA received relevant pharmacological treatments at least as frequently as the AS group. However, there also appears to be room for improvement concerning pharmacological and non-pharmacological treatment, since a high proportion of cases still had symptoms and levels of PROMs suggesting an active axial disease, especially in the group with PsA.
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AS

:   ankylosing spondylitis

ASAS

:   assessment of spondyloarthritis

ATC

:   anatomical therapeutic code

BASDAI

:   Bath Ankylosing Spondylitis Activity Index

BASFI

:   Bath Ankylosing Spondylitis Functionality Index

EQ-5D

:   European Quality of Life-5 Dimensions index

IBD

:   inflammatory bowel disease

IBP

:   inflammatory back pain

ICD-10

:   international classification of diseases

NRS

:   numerical rating scale

NSAID

:   non-steroidal anti-inflammatory drug

PIN

:   personal identification number

PROM

:   patient-reported outcome measure

PsA

:   psoriatic arthritis

ReA

:   reactive arthritis

sDMARD

:   synthetic disease modifying drug

SHCR

:   Skåne Health Care Register

SpA

:   spondyloarthritis

TNFi

:   tumor necrosis factor alfa inhibitor
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